| Related Articles |
Antiangiogenic Therapy in Gastroesophageal Cancer.
Hematol Oncol Clin North Am. 2017 Jun;31(3):499-510
Authors: Jin Z, Yoon HH
Abstract
Antiangiogenesis therapy is one of only 2 biologically targeted approaches shown to improve overall survival over standard of care in advanced adenocarcinoma of the stomach or gastroesophageal junction (GEJ). Therapeutic targeting of vascular endothelial growth factor receptor 2 improves overall survival in patients with previously treated advanced gastric/GEJ adenocarcinoma. No antiangiogenesis therapy has demonstrated an overall survival benefit in patients with chemo-naïve or resectable esophagogastric cancer or in patients whose tumors arise from the esophagus. Promising ongoing clinical investigations include the combination of antiangiogenesis therapy with immune checkpoint inhibition and anti-human epidermal growth factor receptor 2 therapy.
PMID: 28501090 [PubMed - in process]
from #MedicinebyAlexandrosSfakianakis via xlomafota13 on Inoreader http://ift.tt/2pOdjW8
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου